Vanda Pharmaceuticals (VNDA) Common Equity (2009 - 2026)

Vanda Pharmaceuticals has disclosed Common Equity across 18 years of filings, most recently posting $280.8 million for Q1 2026.

• Common Equity for Q1 2026 came in at $280.8 million, down 45.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $280.8 million (down 45.1% YoY), and the FY2025 annual result was $327.2 million, down 39.25% from the prior year.
• Common Equity came in at $280.8 million for Q1 2026 at Vanda Pharmaceuticals, down from $327.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $544.9 million in Q4 2023 to a low of $280.8 million in Q1 2026.
• The 5-year median for Common Equity is $527.2 million (2022), against an average of $497.4 million.
• Across the five-year window, Common Equity advanced 7.38% in 2022 and tumbled 45.1% in 2026, its largest moves.
• Vanda Pharmaceuticals' Common Equity stood at $527.2 million in 2022, then rose by 3.36% to $544.9 million in 2023, then decreased by 1.17% to $538.5 million in 2024, then sank by 39.25% to $327.2 million in 2025, then decreased by 14.19% to $280.8 million in 2026.
• The last three Common Equity figures came in at $280.8 million (Q1 2026), $327.2 million (Q4 2025), and $466.0 million (Q3 2025), per Business Quant data.